Miltenyi Biotec BV & Co. KG

Replay’s oncology-focused product company Syena and Miltenyi Biotec enter into exclusive licensing and GMP manufacturing agreement for PRAME TCR-NK cell therapy based on CliniMACS Prodigy® Syena secures exclusive license to Miltenyi Biotec’s PRAME TCR Syena, co-founded by Replay and MD Anderson in 2023, will develop an off-the-shelf PRAME TCR-NK cell therapy, with IND anticipated Q1 2024 Miltenyi Biotec to supply scalable, GMP-compliant, PRAME-targeted TCR-NK cell therapy product using the CliniMACS Prodigy® system for clinical development and future commercial supply San Diego, California; London, UK and Bergisch Gladbach, Germany, December 18, 2023 – Replay, a genome writing company reprogramming biology by writing, designing and delivering big DNA, and Miltenyi Biotec, a global provider of products and services for biomedical research and cellular therapy, today announced a licensing and manufacturing agreement to support the development of a GMP-compliant T-cell receptor (TCR) natural killer (NK) cell therapy targeting the tumor-associated neoantigen, PRAME. Under the terms of the agreement, Syena, the oncology-focused engineered cell therapy product company launched jointly by Replay and The University of Texas MD Anderson Cancer Center in February 2023, has secured an exclusive license to Miltenyi Biotec’s PRAME (PReferentially expressed Antigen in MElanoma) TCR. Miltenyi Biotec will use its CliniMACS Prodigy® closed and automated cell processing platform to manufacture a scalable, GMP-compliant, PRAME-targeted, TCR-NK cell therapy product for clinical development and provision of future commercial supply. PRAME has been extensively investigated by researchers as a target for cancer immunotherapy. It is highly expressed across a broad range of tumor types and has minimal expression in healthy tissue. It is the second validated cancer neoantigen to be targeted by Syena, which is creating the next generation of off-the-shelf cell therapies combining the safety, tolerability, efficacy, and scalability of NK cells with the ability of TCRs to target intracellular tumor antigens. The Company’s first target, NY-ESO-1, is being investigated in relapsed or refractory multiple myeloma, synovial sarcoma, and myxoid/round cell liposarcoma. Following two recent IND clearances, the Phase I/II clinical studies are anticipated to commence in Q4 of this year. Adrian Woolfson, Executive Chairman, President and Co-Founder of Replay, said: “PRAME is an extensively validated target for immunotherapy in both solid tumors and hematological malignancies. It comprises a compelling addition to our expanding portfolio of targets for our first-in-class engineered TCR-NK cord blood derived cell therapies. We are, additionally, delighted to have Syena partner with Miltenyi Biotec at this early stage to use their CliniMACS Prodigy® cell manufacturing system to lock down our GMP commercial supply.” Lachlan MacKinnon, CEO and Co-Founder of Replay, said: “Miltenyi Biotec’s extensive expertise and manufacturing capabilities will enable us to swiftly advance the clinical development of our cell therapy programs by providing a GMP-grade, commercial-scale supply of cell therapy products. This agreement demonstrates our confidence in our off-the-shelf TCR-NK therapies against a target with significant medical and commercial potential.” Dr Boris Stoffel, Managing Director and Member of the Executive Board of Miltenyi Biotec, said: “At Miltenyi Biotec, we bring over 30 years of expertise in developing innovative products and solutions for cell and gene therapy and biomedical research. In line with our mission to advance cell therapies to treat patients with cancer and other serious diseases, we’re excited to collaborate with Replay and the Syena team on their GMP-compliant PRAME TCR-NK cell therapy product.” Ends About Replay Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies — including a high payload capacity HSV platform, a hypoimmunogenic cell therapy platform, and a genome writing platform — to address the challenges currently limiting clinical progress and preventing genomic medicine from realizing its potential. The Company’s hub-and-spoke business model separates technology development within Replay from therapeutic development in a portfolio of product companies that leverage its technology platforms. For example, the Company recently incorporated a first-in-class engineered TCR-NK cell therapy product company using technology developed by Katy Rezvani, MD, PhD, at The University of Texas MD Anderson Cancer Center in Houston, Texas. Replay’s synHSV™ technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replay’s four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle. Replay is led by a distinguished team of academics, entrepreneurs, and industry experts. The Company raised $55 million in seed financing in July 2022 and is supported by an international syndicate of investors including: KKR, OMX Ventures, ARTIS Ventures, and Lansdowne Partners. Replay is headquartered in San Diego, California. For further information please visit and follow us on LinkedIn and X/Twitter. About Miltenyi Biotec Miltenyi Biotec is a global leader innovating products and services that empower biomedical research and advance cellular therapy. The company's solutions support all stages of cell and gene therapy product development from process and analytical development to commercial-scale manufacturing. Its platform technologies have set industry standards in automated, integrated manufacturing and analysis of complex cellular products such as CAR-T cells, TCR-T cells, gene-modified NK and stem cells. Miltenyi Biotec’s comprehensive product portfolio is complemented by CDMO services for lentiviral vectors and cell manufacturing. The company has more than 4,700 employees in 23 countries and its products have been used in more than 100,000 cell therapy procedures. Miltenyi Bioindustry, as a division of Miltenyi Biotec, uses its end-to-end expertise towards developing and manufacturing lentiviral vectors and cell and gene therapy products based on the CliniMACS Prodigy® fully automated cell manufacturing platform – from pre-clinical to commercial scale. Miltenyi Biotec is headquartered in Bergisch Gladbach, Germany. For further information please visit and follow us on LinkedIn and X/Twitter. Contacts: Replay Dr Adrian Woolfson/Lachlan MacKinnon info@replay.bio Miltenyi Biotec B.V. & Co. KG – Corporate Communications Kim Münster corpcom@miltenyi.com ICR Consilium – Media relations Amber Fennell/Tracy Cheung/David Daley replay@consilium-comms.com

NEW YORK, Oct. 22, 2023 /PRNewswire/ -- According to Technavio, the global flow cytometer market size is estimated to grow by USD 6,038.44 million from 2022 to 2027. The market is estimated to grow at a CAGR of 13.12% during the forecast period. Moreover, the growth momentum will accelerate. The report also includes historic market data from 2017 to 2021. In 2017, the flow cytometer market was valued at USD 4,397.07 million. Technavio has segmented the market based on product (reagents and consumables, instruments, and others) and end-user (pharmaceutical industry, health and diagnostic centers, and others). Continue Reading Technavio has announced its latest market research report titled Global Flow Cytometer Market 2023-2027 The reagents and consumables segment will account for a significant share of the market's growth during the forecast period. The primary functions of these reagents and consumables include cell separation, cell detection, blocking, cell status analysis, performance control, and cell staining. The growth of this segment is attributed to factors such as a high volume of sales and a short product replacement or replenishment cycle. Such factors will drive the segment's growth during the forecast period. The report also provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. For more insights on the market, request a sample report Flow cytometer market - Five forces The global flow cytometer market is fragmented, and the five forces analysis covers– Bargaining power of buyers The threat of new entrants Threat of rivalry Bargaining power of suppliers Threat of substitutes For an interpretation of Porter's five forces model – Buy the report! Flow cytometer market – Customer landscape The report includes the market's adoption lifecycle, from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies. Geography overview Based on geography, the global flow cytometer market is segmented into North America, Europe, Asia, and Rest of World (ROW). The report provides actionable insights and estimates the contribution of all regions to the growth of the global flow cytometer market. North America is estimated to account for 35% of the growth of the global market during the forecast period. This growth is attributed to factors such as the increasing prevalence of several infectious and chronic diseases, the growing presence of pharmaceutical companies, a rise in the development of various therapeutic drugs, and the growing adoption of advanced technologies. Download a sample report Flow cytometer market – Market dynamics Key factor driving market growth The increasing expenditure on R&D is driving the growth of the global flow cytometer market. The increasing prevalence of diseases such as cancer, diabetes, COVID-19, heart diseases, chronic obstructive pulmonary disease (COPD), and dementia has driven the need for developing biologics and small molecules. Pharmaceutical companies are focusing on R&D for the development of new drug molecules to enhance their product pipeline. They are also increasing their R&D expenditure on discovering and developing novel drugs. Thus, the growing demand for advanced technologies is expected to contribute to the growth of the global flow cytometer market during the forecast period. Leading trends influencing the market The increasing level of process automation is a key trend in the market. The level of automation has improved significantly over the last couple of decades. Automation allows the storage of processed information and reduces the need for human intervention. Most instruments and devices used in laboratories can be integrated into a digital ecosystem to enable seamless integration. This will allow higher throughput, better accuracy, more energy efficiency, reduced wastage of resources, and lower operating costs in the long run. Therefore, the global flow cytometer market is expected to grow during the forecast period. Major challenges hindering market growth A shortage of skilled professionals is challenging the growth of the global flow cytometer market. Flow cytometer instruments require advanced analysis software for various measurement procedures. Hence, the operation of these instruments and the analysis of samples requires considerable training. Companies should invest significantly in training their employees on the effective use of these instruments. These devices also need high maintenance, especially for companies in the biopharmaceutical industry. Therefore, the shortage of skilled labor, along with the growing complexity of flow cytometer instruments, will challenge the growth of the market during the forecast period. Drivers and challenges have an impact on market dynamics, which can impact businesses. Find more insights in a sample report! What are the key data covered in this flow cytometer market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the flow cytometer market between 2023 and 2027 Precise estimation of the size of the flow cytometer market and its contribution to the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the flow cytometer market across North America, Europe, Asia, and Rest of World (ROW) A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of Flow Cytometer Market vendors Gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Related Reports: The flow meter market is estimated to grow at a CAGR of 6.4%, and the size of the market is forecasted to increase by USD 3.09 billion between 2022 and 2027. This report extensively covers market segmentation by end-user (industrial, commercial, and residential), type (ultrasonic, magnetic, differential pressure, and others), and geography (APAC, North America, Europe, Middle East and Africa, and South America). The smart gas meters market size is expected to increase by USD 1.97 billion from 2021 to 2026. This report extensively covers market segmentation by technology (AMR and AMI) and geography (Europe, North America, APAC, South America, and Middle East and Africa). Browse for Technavio's information technology market reports Table of contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 (USD million) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 (USD million) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global flow cytometer market 2017 - 2021 Exhibit 18: Historic Market Size – Data Table on Global flow cytometer market 2017 - 2021 (USD million) 4.2 Product Segment Analysis 2017 - 2021 Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 (USD million) 4.3 End-user Segment Analysis 2017 - 2021 Exhibit 20: Historic Market Size – End-user Segment 2017 - 2021 (USD million) 4.4 Geography Segment Analysis 2017 - 2021 Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 (USD million) 4.5 Country Segment Analysis 2017 - 2021 Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 (USD million) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 5.5 Threat of substitutes Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Product 6.1 Market segments Exhibit 30: Chart on Product - Market share 2022-2027 (%) Exhibit 31: Data Table on Product - Market share 2022-2027 (%) 6.2 Comparison by Product Exhibit 32: Chart on Comparison by Product Exhibit 33: Data Table on Comparison by Product 6.3 Reagents and consumables - Market size and forecast 2022-2027 Exhibit 34: Chart on Reagents and consumables - Market size and forecast 2022-2027 (USD million) Exhibit 35: Data Table on Reagents and consumables - Market size and forecast 2022-2027 (USD million) Exhibit 36: Chart on Reagents and consumables - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Reagents and consumables - Year-over-year growth 2022-2027 (%) 6.4 Instruments - Market size and forecast 2022-2027 Exhibit 38: Chart on Instruments - Market size and forecast 2022-2027 (USD million) Exhibit 39: Data Table on Instruments - Market size and forecast 2022-2027 (USD million) Exhibit 40: Chart on Instruments - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Instruments - Year-over-year growth 2022-2027 (%) 6.5 Others - Market size and forecast 2022-2027 Exhibit 42: Chart on Others - Market size and forecast 2022-2027 (USD million) Exhibit 43: Data Table on Others - Market size and forecast 2022-2027 (USD million) Exhibit 44: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibit 45: Data Table on Others - Year-over-year growth 2022-2027 (%) 6.6 Market opportunity by Product Exhibit 46: Market opportunity by Product (USD million) 7 Market Segmentation by End-user 7.1 Market segments Exhibit 47: Chart on End-user - Market share 2022-2027 (%) Exhibit 48: Data Table on End-user - Market share 2022-2027 (%) 7.2 Comparison by End-user Exhibit 49: Chart on Comparison by End-user Exhibit 50: Data Table on Comparison by End-user 7.3 Pharmaceutical industry - Market size and forecast 2022-2027 Exhibit 51: Chart on Pharmaceutical industry - Market size and forecast 2022-2027 (USD million) Exhibit 52: Data Table on Pharmaceutical industry - Market size and forecast 2022-2027 (USD million) Exhibit 53: Chart on Pharmaceutical industry - Year-over-year growth 2022-2027 (%) Exhibit 54: Data Table on Pharmaceutical industry - Year-over-year growth 2022-2027 (%) 7.4 Health and diagnostic centers - Market size and forecast 2022-2027 Exhibit 55: Chart on Health and diagnostic centers - Market size and forecast 2022-2027 (USD million) Exhibit 56: Data Table on Health and diagnostic centers - Market size and forecast 2022-2027 (USD million) Exhibit 57: Chart on Health and diagnostic centers - Year-over-year growth 2022-2027 (%) Exhibit 58: Data Table on Health and diagnostic centers - Year-over-year growth 2022-2027 (%) 7.5 Others - Market size and forecast 2022-2027 Exhibit 59: Chart on Others - Market size and forecast 2022-2027 (USD million) Exhibit 60: Data Table on Others - Market size and forecast 2022-2027 (USD million) Exhibit 61: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibit 62: Data Table on Others - Year-over-year growth 2022-2027 (%) 7.6 Market opportunity by End-user Exhibit 63: Market opportunity by End-user (USD million) 8 Customer Landscape 8.1 Customer landscape overview Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape 9.1 Geographic segmentation Exhibit 65: Chart on Market share by geography 2022-2027 (%) Exhibit 66: Data Table on Market share by geography 2022-2027 (%) 9.2 Geographic comparison Exhibit 67: Chart on Geographic comparison Exhibit 68: Data Table on Geographic comparison 9.3 North America - Market size and forecast 2022-2027 Exhibit 69: Chart on North America - Market size and forecast 2022-2027 (USD million) Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 (USD million) Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.4 Europe - Market size and forecast 2022-2027 Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 (USD million) Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 (USD million) Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.5 Asia - Market size and forecast 2022-2027 Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 (USD million) Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 (USD million) Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%) 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 (USD million) Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 (USD million) Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 9.7 US - Market size and forecast 2022-2027 Exhibit 85: Chart on US - Market size and forecast 2022-2027 (USD million) Exhibit 86: Data Table on US - Market size and forecast 2022-2027 (USD million) Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%) 9.8 China - Market size and forecast 2022-2027 Exhibit 89: Chart on China - Market size and forecast 2022-2027 (USD million) Exhibit 90: Data Table on China - Market size and forecast 2022-2027 (USD million) Exhibit 91: Chart on China - Year-over-year growth 2022-2027 (%) Exhibit 92: Data Table on China - Year-over-year growth 2022-2027 (%) 9.9 UK - Market size and forecast 2022-2027 Exhibit 93: Chart on UK - Market size and forecast 2022-2027 (USD million) Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 (USD million) Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%) 9.10 Germany - Market size and forecast 2022-2027 Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 (USD million) Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 (USD million) Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%) 9.11 Canada - Market size and forecast 2022-2027 Exhibit 101: Chart on Canada - Market size and forecast 2022-2027 (USD million) Exhibit 102: Data Table on Canada - Market size and forecast 2022-2027 (USD million) Exhibit 103: Chart on Canada - Year-over-year growth 2022-2027 (%) Exhibit 104: Data Table on Canada - Year-over-year growth 2022-2027 (%) 9.12 Market opportunity by geography Exhibit 105: Market opportunity by geography (USD million) 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 106: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 107: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 108: Overview on factors of disruption 11.4 Industry risks Exhibit 109: Impact of key risks on business 12 Vendor Analysis 12.1 Vendors covered Exhibit 110: Vendors covered 12.2 Market positioning of vendors Exhibit 111: Matrix on vendor position and classification 12.3 Agilent Technologies Inc. Exhibit 112: Agilent Technologies Inc. - Overview Exhibit 113: Agilent Technologies Inc. - Business segments Exhibit 114: Agilent Technologies Inc. - Key news Exhibit 115: Agilent Technologies Inc. - Key offerings Exhibit 116: Agilent Technologies Inc. - Segment focus 12.4 Amphasys AG Exhibit 117: Amphasys AG - Overview Exhibit 118: Amphasys AG - Product / Service Exhibit 119: Amphasys AG - Key offerings 12.5 Apogee Flow Systems Ltd. Exhibit 120: Apogee Flow Systems Ltd. - Overview Exhibit 121: Apogee Flow Systems Ltd. - Product / Service Exhibit 122: Apogee Flow Systems Ltd. - Key offerings 12.6 Becton Dickinson and Co. Exhibit 123: Becton Dickinson and Co. - Overview Exhibit 124: Becton Dickinson and Co. - Business segments Exhibit 125: Becton Dickinson and Co. - Key news Exhibit 126: Becton Dickinson and Co. - Key offerings Exhibit 127: Becton Dickinson and Co. - Segment focus 12.7 Bio Rad Laboratories Inc. Exhibit 128: Bio Rad Laboratories Inc. - Overview Exhibit 129: Bio Rad Laboratories Inc. - Business segments Exhibit 130: Bio Rad Laboratories Inc. - Key news Exhibit 131: Bio Rad Laboratories Inc. - Key offerings Exhibit 132: Bio Rad Laboratories Inc. - Segment focus 12.8 Cytek Biosciences Inc. Exhibit 133: Cytek Biosciences Inc. - Overview Exhibit 134: Cytek Biosciences Inc. - Product / Service Exhibit 135: Cytek Biosciences Inc. - Key offerings 12.9 Danaher Corp. Exhibit 136: Danaher Corp. - Overview Exhibit 137: Danaher Corp. - Business segments Exhibit 138: Danaher Corp. - Key news Exhibit 139: Danaher Corp. - Key offerings Exhibit 140: Danaher Corp. - Segment focus 12.10 DiaSorin SpA Exhibit 141: DiaSorin SpA - Overview Exhibit 142: DiaSorin SpA - Business segments Exhibit 143: DiaSorin SpA - Key news Exhibit 144: DiaSorin SpA - Key offerings Exhibit 145: DiaSorin SpA - Segment focus 12.11 Enzo Biochem Inc. Exhibit 146: Enzo Biochem Inc. - Overview Exhibit 147: Enzo Biochem Inc. - Product / Service Exhibit 148: Enzo Biochem Inc. - Key offerings 12.12 Miltenyi Biotec B.V. and Co. KG Exhibit 149: Miltenyi Biotec B.V. and Co. KG - Overview Exhibit 150: Miltenyi Biotec B.V. and Co. KG - Product / Service Exhibit 151: Miltenyi Biotec B.V. and Co. KG - Key news Exhibit 152: Miltenyi Biotec B.V. and Co. KG - Key offerings 12.13 Sartorius AG Exhibit 153: Sartorius AG - Overview Exhibit 154: Sartorius AG - Business segments Exhibit 155: Sartorius AG - Key news Exhibit 156: Sartorius AG - Key offerings Exhibit 157: Sartorius AG - Segment focus 12.14 Sony Group Corp. Exhibit 158: Sony Group Corp. - Overview Exhibit 159: Sony Group Corp. - Business segments Exhibit 160: Sony Group Corp. - Key news Exhibit 161: Sony Group Corp. - Key offerings Exhibit 162: Sony Group Corp. - Segment focus 12.15 Stratedigm Inc. Exhibit 163: Stratedigm Inc. - Overview Exhibit 164: Stratedigm Inc. - Product / Service Exhibit 165: Stratedigm Inc. - Key offerings 12.16 Sysmex Corp. Exhibit 166: Sysmex Corp. - Overview Exhibit 167: Sysmex Corp. - Business segments Exhibit 168: Sysmex Corp. - Key offerings Exhibit 169: Sysmex Corp. - Segment focus 12.17 Thermo Fisher Scientific Inc. Exhibit 170: Thermo Fisher Scientific Inc. - Overview Exhibit 171: Thermo Fisher Scientific Inc. - Business segments Exhibit 172: Thermo Fisher Scientific Inc. - Key news Exhibit 173: Thermo Fisher Scientific Inc. - Key offerings Exhibit 174: Thermo Fisher Scientific Inc. - Segment focus 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 175: Inclusions checklist Exhibit 176: Exclusions checklist 13.3 Currency conversion rates for USUSD Exhibit 177: Currency conversion rates for USUSD 13.4 Research methodology Exhibit 178: Research methodology Exhibit 179: Validation techniques employed for market sizing Exhibit 180: Information sources 13.5 List of abbreviations Exhibit 181: List of abbreviations About US Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

ZURICH, March 15, 2023 /PRNewswire/ -- lino Biotech, a leading biosensor company and the world's only provider of Focal Molography, announced today it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023. Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy manufacturing, and testing for off-target responses in living cells to support drug discovery. Headquartered in Bergisch Gladbach, Miltenyi Biotech has been a global provider of products and services for biomedical research and cellular therapy for more than 30 years. Under the terms of the transaction, Miltenyi Biotech will acquire 100% of the shares from the investors including Roche Venture Fund and High-Tech Gründerfonds. The specific terms of the transaction were not disclosed. "lino´s innovative biosensor platform and Miltenyi's cell and gene therapy approaches offer exciting synergies to lower the cost and establish a new standard for potency assays," said Dr. Mirko Stange, CEO of lino Biotech. lino's headquarters in Zurich will be further expanded for research, chip, and application development. About lino Biotech AG: lino Biotech AG was incorporated as ETH Zurich spin-out in Zürich, Switzerland, in March 2020, and is venture backed by Roche Venture Fund, High-Tech Gründerfonds and several life science family offices. lino Biotech is a life science tools company that develops reagent-free biosensors and readers to measure pharmaceutical relevant biological entities directly from crude samples such as bioprocess reactors solutions. The company's ability to provide target-specific binding information in a faster, very sensitive and cost-effective manner can lower R&D and production cost for pharma and biotech customers and offers an opportunity to make novel Cell & Gene therapies accessible to more patients. About Miltenyi Biotec B.V. & Co.KG: Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 4,500 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health. Press Contact: Wordstatt GmbH [email protected] +49-172-8312173 SOURCE lino Biotech AG